OR WAIT 15 SECS
The new facility, to be built in Toronto, Canada, will significantly increase capacity for pediatric and booster vaccines.
On April 12, 2018, Sanofi announced that it is investing EUR 350 million (US$431 million) to construct a new vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario, Canada. The investment bolsters the company’s Canadian operations.
The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP) antigen. The new building is expected to be completed in 2021 and will be equipped to produce the antigens used in the diphtheria and tetanus vaccines.
“Canada has a strong legacy in the research and development of vaccines. With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe,” said David Loew, executive vice president and head of Sanofi Pasteur, in a company press release. “Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease.”
“This project is one of the most important investments for the Sanofi global industrial network,” said Philippe Luscan, executive vice president, Global Industrial Affairs, Sanofi, in the press release. “It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world.”